Balancing Science, Ethics and Politics: Stem Cell Research, a Paradigm Case by Pellegrino, Edmund D.
Journal of Contemporary Health Law & Policy (1985-2015) 
Volume 18 Issue 3 Article 3 
2002 
Balancing Science, Ethics and Politics: Stem Cell Research, a 
Paradigm Case 
Edmund D. Pellegrino 
Follow this and additional works at: https://scholarship.law.edu/jchlp 
 Part of the Health Law and Policy Commons 
Recommended Citation 
Edmund D. Pellegrino, Balancing Science, Ethics and Politics: Stem Cell Research, a Paradigm Case, 18 J. 
Contemp. Health L. & Pol'y 591 (2002). 
Available at: https://scholarship.law.edu/jchlp/vol18/iss3/3 
This Article is brought to you for free and open access by CUA Law Scholarship Repository. It has been accepted 
for inclusion in Journal of Contemporary Health Law & Policy (1985-2015) by an authorized editor of CUA Law 
Scholarship Repository. For more information, please contact edinger@law.edu. 
ARTICLES
BALANCING SCIENCE, ETHICS AND
POLITICS: STEM CELL RESEARCH, A
PARADIGM CASE
E.D. Pellegrino, M.D.
INTRODUCTION
Every truly effective technological advance is a challenge to culture,
politics and ethics. This is as true for the discoveries of fire, the wheel and
gunpowder, as it is for the Atom Bomb, space travel and biotechnology.
The more effective the technology, the more serious the challenges it
poses.
Thomas Merton, with his acute sensitivity to the malaise of the soul of
modern man, put it this way: "...the problem of getting technology back
into the power of man so that it may be used for man's own good is by all
odds the great problem of the day.'''
At this writing, after the horrendous assault on human life in the
terrorist attacks of September 11th, the "problem" of technology is easily
displaced by the problem of injustice and violence of man against his
fellow man. Yet on this same day, the National Academy of Sciences
released its report and recommendation regarding Stem Cell research.2
We are just beginning to confront the challenge of biotechnology, a form
of technology more personal, intimate and more challenging to our
concept of what it is to be human than any past technological "advances,"
with the possible exception of the atom bomb. How do we use our
technological prowess humanely, wisely and generously without being so
overshadowed by its powers that we become its slaves?
How in essence do we place biotechnology within ethical constraints
without losing its therapeutic potential? How do we do so in a democratic,
morally and pluralistically divided society, driven equally by market forces
and a yearning for immortality through technology?
1. Thomas Merton, The Hidden Ground of Love, in LETTERS OF THOMAS
MERTON, 507 (William H. Shannon, ed.) (1985).
2. NATIONAL ACADEMIES OF SCIENCES, STEM CELLS: SCIENTIFIC PROGRESS
AND THE FUTURE OF REGENERATIVE MEDICINE (2001).
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Stem Cell Research is a paradigm case illustrating the complex
intersections of science, ethics and politics, which will characterize any
powerful new technology. This essay seeks to outline the intersections of
science, ethics and politics through which society shall navigate in the
years ahead. The stem cell research issue will serve as an example for
analyzing the questions the whole citizenry must confront with the
introduction of biotechnological progress - not just scientists, bioethicists
or legislators.
As a physician and a patient, the author sympathizes with the
tremendous desire to make rapid progress in the therapeutic use of the
fruits of our new knowledge. Persons of good will can differ on the nature,
application and source of ethical constraints on research. The search for
biological knowledge - within ethical constraints- should be praised and
supported. However, the ethical, political, scientific and economic issues
cannot totally be disentangled. If there is to be some moral order in the
approach to policy formation and legislation, then there must be some
moral compass points to guide both science and policy. No matter how
much human good we envision, we cannot allow our zeal for knowledge,
power, profit or even cure to displace our humanity.
There are three fundamental questions, and sets of relationships, which
recur in any legislation or policy regarding the application of biological
knowledge in the public arena. This paper will discuss three sets of
questions, which anchor the debate and define the moral quality of policy
and legislation.
First, what scientific facts support stem cell research and how secure are
they? Second, what fundamental ethical issues are at stake? Third, what
are the implications of questions one and two for politico-economic
policy?
I. WHAT SCIENTIFIC FACTS SUPPORT STEM CELL
RESEARCH AND HOW SECURE ARE THEY?
In any situation, good policy and good ethics depend on good facts.
Even so, the individuals who gather and assess the facts are not the same
ones who must make public policy or legislate. These latter must
nevertheless base their decisions on the testimony of experts. They must
probe expert testimony critically if they are to avoid automatic
capitulation to the aura of authority that follows expertise. This can be
extremely difficult to accomplish since scientists may honestly disagree
about the same issue. The same data may be subject to different
interpretations. This factor neither accuses scientists of insincerity nor
deception, but emphasizes that legislators and the public must probe
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scientific claims carefully if they wish to legislate and regulate wisely. This
is especially true when prestige, power and profit are so evidently at stake
as they are in stem cell research.
These concerns are not confined to legislators or policy makers.
Ultimately they are matters of concern for every citizen. Bioethics is no
longer the restricted terrain of physicians and health professionals, nor of
bioethicisists. The ethical issues are pertinent for the lives of all of us in
the present and in future generations.
Let us look at a few examples of current stem cell research to illustrate
this point more concretely. The discussion will focus on expectations of
cure, terminology, the utility of existing stem cell lines and alternate
sources.
A. Terminology
Stem cells are unspecialized cells found in the human embryo, fetus
(germ cells) and adult. They are characterized by great plasticity, i.e., they
can, spontaneously or by manipulation, are converted into the many types
of specialized cells making up the human body. Those taken from very
early embryos are "totipotent", i.e., capable of developing into a complete
new human being. Others taken at later stages of embryonic development
are "pluripotent," transformable into all other types of cells but not into a
full and complete human being. Stem cells can also be found in adult
human tissues, such as bone marrow, brain, muscle, umbilical cord blood,
liver, and fetal tissue.
"Embryonic stem cells" are usually harvested for experimental or
therapeutic purposes from embryos five days old. "Harvesting" these cells
inevitably results in the death of the embryo. Thus, whether the
embryonic stem cells are toti- or pluripotent, use of them poses two ethical
challenges. First, they are obtained through deliberate killing of the
embryo, and second, if they are gathered at an early stage, they are
totipotent and can develop into complete human beings. Therefore, the
source of embryonic stem cells and their age are ethically significant in an
evaluation of the legitimacy of their use.
Another manner in which to obtain embryonic stem cells is somatic Cell
Nuclear Transfer, or cloning. Through this method, a totipotential cell is
produced which could, under the proper circumstances, become a
complete human adult. This cell is grown in culture until it is five to seven
days old, then its inner cell mass is harvested. This process, again, results
in death of the embryo. This is an example of human cloning which is
currently subject to a congressional ban. To circumvent this ban, it has
been suggested that the term "nuclear transplantation" be used instead.
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This semantic device does not alter the fact that a human embryo is
destroyed for its stem cells.
A new method has recently been proposed for obtaining stem cells
through a process called therapeutic cloning. The goal is to clone human
embryos containing genes from a patient in hopes that the clone will
produce normal cells that can then be implanted in the same patient
without an adverse immune system response. The first attempts using
nuclear transfer failed. Another attempt using unfertilized eggs artificially
stimulated to undergo cleavage produced a blastocoele cavity but no stem
cells.
This is the process of parthenogenesis and the cells thus produced are
called "parthenotes." Parthenogenesis occurs naturally in simple species,
but it has never been accomplished in mammals. Stem cells from
parthenotes do not have the genetic make up to become a full term baby.3
Much depends upon whether the stem cells derived from so-called
"excess" frozen embryos are totipotential or pluripotential. This is no
mere semantic quibble. If they are totipotential and each can develop into
a complete human being, then one is creating, experimenting with and
killing a human embryo. If stem cells are not human embryos and not
totipotential, then they can legitimately be used for experimentation and
therapeutics. If there is a reasonable doubt, as any honest evaluation of
the issue must conclude, the embryo deserves the benefit of that doubt
and should not be used. After all, in most matters few of us would gamble
what we cannot afford to lose.
Contemporary embryologists regard embryonic cells as totipotent from
the zygote stage (the fertilized egg) through the blastula (four cell stage)
and possibly up to the blastocyst (five to seven days). If these dividing
cells are separated from each other in these early stages they are
totipotent, meaning each one can develop into a complete human being.
How far beyond the blastula the embryonic cells remain totipotent or can
recover their totipotency is uncertain with the embryologic evidence now
in hand. If at any point embryonic cells can become complete human
beings, ethical objections arise not just with the source of such cells, but
with their use, regardless of the source.
Much also depends upon whether or not the cells of the frozen embryos
to be used to replenish existing cell lines are young enough to be
totipotent. There is some evidence that some of these cells at least may be
3. "Cloning Announcement Sparks Debate and Scientific Skepticism," in
SCIENCE. Nov. 30, 2001, at 1802. These scientists include O'Rahilly, Muller,
Carlson, Sher, Davis and Stoess.
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at the four to eight cell stage or somewhere between the blastula and the
blastocyst stage when frozen. If this turns out to be the case, they could
not be used under existing Congressional guidelines, which preclude
experimentation with human embryos.
This raises the question of how we define an embryo. Authoritative
Modern Biologists4 regard the embryo to be present from the zygote stage
or right after it begins to divide. Some embryologists and bioethicists
speak of the "pre-embryo," postulating a stage from the zygote until the
fourteenth day before which they do not consider the developing cells an
"embryo." There is no biological warrant for such an arbitrary distinction.
Rather, it has the earmarks of a convenient means for justifying treatment
of the developing human with less respect than one would grant it after
fourteen days. In much the same way, it has been recommended that the
term "ES Cell" be used rather than Embryonic Stem cell to avoid the
stigma of destroying human embryos, thus defining the embryo out of
existence through a semantic ploy. The nature of the organism is not
changed by changing its name.
Clearly, precision in scientific terminology is far more than an exercise
in pedantry or taxonomy. Until the biological status of embryonic stem
cells and their potentialities at each stage of development are clearly
demonstrated, these cells should be given the benefit of the doubt and
protected from destruction. Given the genuine probability that adult stem
cells, in association with pharmacological and genetic manipulation, can be
as useful therapeutically as embryonic cells, it is morally prudent and
mandatory to concentrate on adult cells. This is a morally and
scientifically sound position whether or not one favors, or objects to, the
use of embryonic stem cells.
Similar controversy surrounds the debate of whether the embryo is
classified as a human person. This is an even more complicated question
than the question of totipotency or what is an embryo. One need only
point out that the zygote is the result of two living cells, and both are
human cells. There can be no question of the earliest stages of human life
being both human and living. Whether or not the embryo is considered a
person is a metaphysical question not susceptible to scientific proof or
falsifiability. Any attempt to define "person" in terms of a set of arbitrary
biological, physiological or sentient qualities is dangerous. Embryos,
fetuses and even impaired members of the human species may lack one or
another of the arbitrarily specified properties for personhood. Persons in
4. O'Rahilly, Muller, Carlson, Sher, Davis and Stoes are representative of
these modern biologists.
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coma, a permanent vegetative state, the retarded and the brain damaged
human are all at risk of being deprived of "personhood" and of social
moral right to protection against harm or destruction.
Alertness to terminology is essential in the stem cell controversy. Those
who favor the destruction of embryos as a source want to avoid use of the
term "embryo" because they think it is too inflammatory and generates
resistance. They suggest a variety of euphemisms: "nuclear
transplantation" or "therapeutic cellular transfer" for cloning humans.
One ethicist, who heads the ethics panel of one of the involved companies
- Advanced Cell - wants to substitute "activated egg" or "cleaving egg"
for the term embryo. Another biologist offers "ovasome."'
These euphemisms are intended to confuse the non-scientist public and
decision-makers and divert their attention from the fundamental fact that
human embryos are produced to be destroyed, - a practice currently at
least subject to congressional ban. All terms used to support or denounce
embryo sacrifice should be defined clearly. Non-scientists must not be
reluctant to question a scientist who, like other humans, may have a vested
interest in avoiding confronting some disturbing ethical challenges.
B. Therapeutic Claims
In the minds of many, including those who have reservations about the
use of human embryos, the claims for therapeutic success seem
overwhelming. Most of the public's information come from the popular
media, which customarily celebrates whatever is new and sensational, or
represents "progress." To be sure, responsible journalists and scientists
have reported the scientific promise as well as the limitations of current
research fairly and accurately. On the whole, however, the public has
been exposed to a species of evangelical advertising, over promise and
semantic prestidigitation overstatement that is morally and scientifically
irresponsible.
The fact of the matter is that no one has yet been cured by the
transplantation of embryonic stem cells. In fact, the one controlled trial of
fetal tissue transfer in Parkinson's disease has resulted in failure and even
worsening of the disease . One cannot deny the potentialities, the need
and the understandable sense of urgency for new therapeutic hope among
5. Sheryl Gay Stolberg, That Scientific Breakthrough Thing, N.Y.TIMES, Dec.
9, 2001, at 3.
6. Spencer, et al., Unilateral Transplantation of Human Fetal Mesenpephalic
Tissue into the Caudate Nucleus of Patients with Parkinson's Disease, 327 NEW
ENG. J. MED. 1541, 1548 (1992).
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patients and families currently afflicted with an incurable disease.
Attempts at moderation of expectations, critical analysis of data and the
need for time to evaluate results are unfortunately regarded as
insensitivity to human suffering, or an anti-science attitude. This attitude
fails to take into account the even greater harm of raising expectations
unrealistically and then failing to deliver on them. The fact of the matter
is that miraculous cures are a long way off in the future.
What has not been sufficiently emphasized in the popular press and the
media is the simple fact that clinical application of stem cells is in its
infancy and the requisite scientific knowledge is still lacking. Very little is
known about the intracellular signals that initiate and direct
differentiation of cells. Equally little is known about what turns genes
"on" and "off," about what controls expression and silencing of genes, or
about the role of chromatin, the protein-DNA complex that helps DNA
enter the nucleus or the enzymes that modify these proteins.
A whole new area of investigation called "epigenetics" has emerged to
modify our conception of the gene as the unit of inheritance No doubt as
these new complex molecular and enzymatic entities are studied new
complexities and new possibilities are certain to reveal themselves. The
same can be said of the process of methylation of DNA in both healthy
and cancer cells. Much remains to be learned about how the unspecialized
stem cells can be made to become the specialized cells before therapy
becomes a reality.
Another problem to be resolved is that of immune rejection of
transplanted embryonic stem cells. This is the result of admixture with
mouse cells now used as a means of accelerating growth. Obtaining stem
cells by somatic cell nuclear transfer, or cloning, could prevent this, but it
requires the production of a new embryo that would have to be destroyed
to harvest its stem cells.
There is an enormous amount of research still to be accomplished in the
fundamental cellular mechanisms if therapeutic applications are ever to
become a reality. Like the Human Genome Project, the discoveries to
date are only the end of the beginning. The public, policy makers and
legislators must recognize the need for increased and superior research
whenever they are subjected to public pressure to "do something." That
research should focus on adult sources of stem cells - not on embryonic
stem cells.
7. Elizabeth Pennisi, Behind the Scenes of Gene Expression, in SCIENCE, 2001,
at 1064.
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C. Limitations of Existing Cell Lines
In August 2001, President Bush ordered that federal funds be used to
support stem cell research only under specified conditions. Specifically,
embryonic stem cells had to have been derived prior to August 9th, the
donors had to provide informed consent, the only approved source for
embryonic stem cells had to be "excess" embryos created solely for
reproductive purposes and no financial inducements for donors and funds
would be provided for research on adult stem cells.
Since the President approved the use of federal funds for research in
existing stem cell lines, new controversy has erupted about the number,
viability, utility and sufficiency of the forty-to-sixty cell lines. The actual
number is in dispute. Recent newspaper articles provide conflicting
information. A survey of fertility clinics, for example, indicates that few
"parents" of frozen embryos have come forward to offer them for
research. Moreover, the number of cell lines actually in a viable or useful
state is highly uncertain. One large source cited by the NIH is in Sweden;
a spokesman from that laboratory has publicly stated that the number of
available cell lines is far too high and that the number in a useful condition
may be much smaller.
In addition, it is reported that perhaps a majority of the frozen embryos
to be used to cultivate cell lines come from older patients and might not be
of sufficient quality or viability to generate useful cell lines. Also, as cell
lines age, harmful mutations occur. This is true of frozen embryos as well.
Optimism about existing cell lines is also dampened by the fact that
existing cell lines had to be "coaxed" to grow by incubating them with
mouse cells. This raises the question of immuno-rejection problems and
the possible introduction of some unknown virus into human recipients.
All of these factors are coupled with a complicated and discouraging
consent process. These factors have already raised a clamor for many
more and newer cell lines, for fresh and better-prepared cell lines, and for
relaxing the prohibition against creating new embryos as the source for
those new cell lines. Progression down the slippery slope toward
unrestrained research with embryonic stem cells is already underway.
Another limitation on the use of existing cell lines has evoked little
discussion so far.9 Most of the existing lines have come from small
segments of the human population. In the West, most of cells now
8. Gina Kolata, Researchers Say Embryos in Labs Aren't Available, N.Y.
TIMES, Aug. 26, 2001, at 1.
9. Jon Entine & Sally Satel, Race Belongs in the Stem Cell Debate, WASH.
POST, Sept. 9, 2001, at B1.
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available come from the U.S., Sweden and Israel; in the East, they come
from South and East Asia. This is a limited representation of the racial,
genetic and ethnic diversity of today's world.
It is true that humans share most of their 30,000 or so genes. However,
there are some subtle yet important differences in their expression to be
understood in the face of the propensity of certain populations to exhibit
high prevalencies of certain diseases, such as Diabetes,
Hemoglobodinopathios, Hypocholesteronemia and Hypertension. Similar
differences exist in the response to a variety of medications or in the
immune reaction to transplanted cells. A new field of pharmacogenetics
has emerged to study some of these differences in drug reactions by
individuals and ethnic groups.
The narrowness of the ethnic and genetic spectrum of existing cell lines
means that research on fundamental mechanisms may not be readily
transferable between and among ethnic groups. If there were therapeutic
benefits forthcoming, they would be limited, at present, to those of
European and some small number of Asian ancestries. This
differentiation is also a matter of justice. For these reasons, the political
pressure to expand and extend stem cell research beyond the lines
approved by President Bush will increase. This in turn will generate
demand for making and destroying more embryos as sources for the
needed cells.
Clearly, many scientific questions remain to be investigated before stem
cells from any source can fulfill the enthusiastic promissory notes made for
their curative posers. What are the best conditions for growing these cells
and shaping the directions their development will take? What genes
control the way the stem cells grow and differentiate? What are the
immediate and remote steps in differentiation? What turns the genes
"on" what turns them "off"? How can immune rejection of injected cells
be prevented? Even more fundamental is the series of critical questions
arising from the emerging field of epigenetics, the realm of research
examining the place of Chromatin and Histones in influencing the DNA
and its functioning. This is a relatively new sector of cellular biology that
may reveal it has as much, or more, influence on how genes function than
DNA itself.'°
These are all complex questions, which should be answered before
acceptable treatment protocols become practicable. Answering these
questions will require many stem cells and many experimental
observations in order to analyze them satisfactorily. As the overestimates
10. Pennisi, supra, note 7, at 1064-1070.
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of the utility of existing cell lines suggest, many more new cell lines will be
demanded." Pressure to relax the President's conditions, particularly his
restrictions on the production of new embryos, will be extremely difficult
to resist. If promising therapeutic reports come from experimental animal
models of disease, then the "slippery slope" will be further greased.
These difficulties make it necessary to focus new attention on alternate
sources for stem cells, chiefly those not involving the death of human
embryos. It is providential that President Bush has set aside federal funds
to support research on alternate sources of stem cells derived from tissues
as varied as bone marrow, placental cord blood, muscle, bone and brain.
Animal studies indicate success in converting mouse bone marrow cells
into brain cells (glia), mouse skeletal muscle into all major blood cell types
even on second transplantation, adult marrow cells into brain, human
stromal cells into rat neurons, and neural cells into lymphoid and myeloid
cells. The scientific community should vigorously pursue all of these
possibilities.
The possibilities and limitations of adult stem cells must be appreciated
as well. Some of their advantages based on recent investigations include:
(1) stem cells of several types are already pre-disposed biologically to
generate a particular tissue and thus might be able to produce that tissue
or its components more readily than less specialized stem cells; (2) they
secrete growth factors, which might facilitate growth of other cells as well
in a transplanted tissue site; (3) some adult stem cells have been shown to
migrate to an injured tissue or other sites, for example, neutral stem cells
to brain tumor sites; and (4) they might be genetically engineered to
produce other compounds normally needed, but deficient, or even to
secrete a drug for therapeutic purposes.
Along with these advantages are certain current disadvantages when
using adult stem cells: (1) they are difficult to isolate; (2) their plasticity
might be minimal; (3) it is not known how to culture environment affects
their functions; and (4) they may not remain undifferentiated or even fail
to become differentiated into functional cells. These questions can be
resolved by intensive research on adult stem cells, which would be
ethically permissible since such research does not involve the death of
embryos.
There is also the possibility that embryonic stem cells are not
experimentally more beneficial than cells from these adult sources with
regard to their plasticity or the possibility of transformation into useful cell
types. The emphasis placed on the supposed superiority of embryonic
11. National Academy of Sciences Report, 2001, recommendations 1& 2.
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stem cells may even be misplaced on strictly scientific grounds. Attention
must be turned to other sources that lack the moral objections that
accompany the use of embryonic stem cells.
II. WHAT ETHICAL ISSUES ARE AT STAKE?
As difficult as the assessment of scientific facts may be, stem cell
research is further complicated by the need to place those facts within an
ethical framework. The mere fact that a therapeutic benefit may be
scientifically demonstrable is insufficient to justify its adoption. The
challenge in a technologically oriented society is to use capabilities wisely,
humanely and within ethical constraints. In a morally pluralist society like
ours, the identification, validation and application of moral norms is
laborious and controversial. Often, no ethically satisfactory compromise is
possible. Regardless, every effort must be made to confront the ethical
questions first.
Certain foundational ethical norms and principles must be examined to
make this analysis. Admittedly, they may be defined, interpreted or
applied in different ways. Nevertheless, a few moral principles will make
their appearance recurrently in the debates. These principles have been
prominent in the paradigm case of stem cell research. The ordering of
science in relation to politics must be done in an ethical framework, or its
decisions will simply be reduced to expediency or exigency.
A. The Ethics of Science
The first ethical norm is the norm of good science, or science that fulfills
the obligations of the scientist as scientist. Much of what has been
discussed thus far in this essay relates to the ethics of good science,
establishing certainty with the factual foundations of the information
supplied by one's colleagues, the public and the policy makers. This
means accuracy and honesty in both reporting and sharing those results so
that they can be falsified or validated by other investigators. It also means
providing negative as well as positive evidence for one's hypothesis or
experimental results.
In the case of therapeutic research, special attention must be placed on
these requirements for several reasons. First, the anxiety and eagerness
for a cure for those afflicted with any illness for which a new treatment is
described must be considered. Second, the implication for public policy if
a new technique or treatment will be made widely available is another
factor. Third, the whole realm of ethical implications to society when the
data focuses on control of some aspect of the beginning and ending of
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human life is also significant. Economy of pretension is a particular virtue
for the responsible scientist.
B. Respect for the Dignity of the Human Being
The moral use of biotechnology must recognize the inherent worth of
the human being as a human, and as a being capable of a rational self-
determining existence. Most of the rights in the United Nations
Declaration are expressions of this principle, such as the right to life,
liberty, freedom from oppression, equality of opportunity and access to
health care.12
In the stem cell controversy, the focal issue is the moral status of the
embryo. At what stage of human development do we impute respect for
the dignity of that embryo? It does not help to evade the issue by the
invention of euphemisms like the "pre-embryo" or the "ES Cell" for
embryonic stem cells. Nor does it help to reduce a metaphysical concept
like personhood to a biological construction. Personhood is not definable
in terms of length of gestation, development of certain anatomical
structures or the capacity for sentiency or social relationships.
Such definitions are far too often semantic contrivances designed to
escape the stigma of destroying a human life in its earliest and most
vulnerable stages. Moreover, these definitions would also exclude from
personhood those persons afflicted by mental retardation, senility, or lack
some modicum prescribed of physiological or other sociological
characteristics arbitrarily defined.
From the philosophical point of view, the embryo is a human being in
the state of active potency. That is to say that from its inception, the
embryo is set on a course of development, which will actualize its
potentialities. Unless interrupted by man or nature, the embryo possesses
the characteristics essential to a human being at the earliest stages of its
development. It is actually, not just potentially, a human being.
Consequently, destruction of an embryo is the destruction of a human
being. Stem cell research, any method of which relies on the death of the
embryo as a step in stem cell retrieval, is morally wrong. This contravenes
use of fertilized zygotes, embryos or clones human ova. Use of adult stem
cells would be licit unless they were made first to made embryos.
C. Avoiding Evil Even if Good Comes of It
In a highly pragmatic society like ours, the probability of a good result
for many, or for a noble cause, may well override the respect owed
12. Universal Declaration of Human Rights, 1948-1998.
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humans. Harm to some humans is thus justifiable if it will help others or
benefit the common good. Human decisions are made with some good in
mind, therefore what is evil is always done under the appearance of good.
This is the argument of those who justify destruction of human embryos
on utilitarian grounds to obtain cells for experimental or therapeutic
purposes. The "special" nature of the embryo will be "recognized," but it
will be set aside if its death can bring life to others. This is the argument
now being used to justify relaxation of the congressional and presidential
ban on producing new embryos or establishing new cell lines. It is also
essentially the argument used by the President's National Bioethics
Commission to justify embryonic stem cell research.
What is at issue here is a choice between two theories of ethics -
consequentialism and deontology. The former argues that the morality of
an act depends upon whether its consequences are so good that they
outweigh the wrong necessary to bring those consequences about. The
deontological view holds to the contrary, that certain acts are so wrong in
themselves that they may never be done even if good may come of it. Of
course, if one holds that there is no wrong done in destroying very young
embryos in the first place, then the debate becomes moot. In any case, the
question must be faced that some choice must be made between truly
respecting the human embryo and overriding that respect when the
embryo's death provides significant benefits for others.
D. Avoiding Complicity
Even if one does not do harm oneself, one may share in the guilt of an
ethically improper act or decision. The degree of moral complicity in a
morally wrong act will depend upon whether or not the wrong intent is
shared and how closely one facilitates the wrong act. The resulting "moral
distance" is crucial in separating morally licit from illicit cooperation. This
is not the place to review the well-established distinctions between
different degrees of moral complicity. 3 Better familiarity with the ethics
of cooperation is requisite if moral judgment is to be made about the use
of embryonic stem cells obtained by the destruction of embryos, even if
one does not do the actual destroying oneself.
This is necessary because some investigators have tried to escape
association with the killing of embryos to obtain their stem cells or avoid
the congressional sanction against such use with federal funds. They do so
by using cells obtained in this manner under private auspices.
13. ORVILLE N. GRIESE, CATHOLIC IDENTITY IN HEALTH CARE: PRINCIPLES
AND PRACTICE, p.373-419 (The Pope John Center 1987).
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Nevertheless, using cells obtained from the death of human embryos is an
instance of moral complicity. An individual shares the intent for which
these cells were harvested when one uses them for experimental or
therapeutic purposes. One also encourages further harvesting by
providing an outlet for the cells thus obtained.
E. The Reality of the Slippery Slope
Once a major moral principle is compromised it becomes incrementally
easy to extend that compromise to analogous or similar cases. Logically,
one finds it difficult not to assent to extension of the compromise to
similar related cases. With each incremental compromise the principle
becomes progressively diluted until it becomes all but non-existent. Little
is left that can be defended.
Once a principle is relaxed, it becomes easier psychologically to accept
compromises even of morally robust norms. It is always the first infraction
that is most difficult. Moral revulsion, once some individuals are able to
overcome it, loses its power to restrain others. Moral revulsion is easier to
overcome with each subsequent compromise. Although many ethicists
revile the slippery slope and label it a myth, they fly in the face of logic,
psychology, history and fact when they do so.
One needs only recall here the history of Roe v. Wade to see this
principle in action. First, abortion was limited to the first trimester, then
allowed in the second and third, and then to late term pregnancy. Going
from the evacuation of a week old fetus to the evacuation of the living
brain of an easily identified human baby in late term abortion is the
inevitable result. Similarly, assisted suicide and euthanasia in the
Netherlands began with certain restrictions for physical illness and
"unbearable" suffering. Today it has been extended to children, infants
and psychological suffering as well. All this has occurred despite
regulations and laws designed to control abuse.14
Already, the National Academy of Sciences has stated that research will
be impeded if it is confined to currently available cell lines, as the
President's decision requires. The National Academy emphasizes that
mutations occur as cell lines age and become less useful as a result. In
addition, current cell lines have been admixed with animal cells, raising
the probability of immunogenetic responses if they are transplanted into
humans. Furthermore, the Academy Report asserts that private
14. E.D. Pellegrino, THE FALSE PROMISE OF BENEFICENT KILLING IN
REGULATING How WE DIE (Linda Emanuel ed., Harvard University Press 1998).
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entrepreneurs are unlikely to develop new lines of cells until the profit
potential is more apparent15
In the stem cell controversy, there is already mounting pressure to use
federal funds to support to use of cells obtained from killing of embryos
under private auspices not supported by private funds. Already the
quality, quantity, and variety of existing stem cell lines is insufficient, and
more embryos must be created to make needed research possible. In the
same way the actual totipotentiality of embryonic stem cells is being re-
interpreted as pluripotentiality - ostensibly to avoid the stigma of
destroying cells from early embryos each of which is capable of, on its
own, becoming a complete new human being. The slippery slope is as
applicable to compromise in the meaning and use of words as it is with
respect to principles and actions.
This is not, nor is it intended to be, the sum total of relevant ethical
principles requisite to an analysis of policy formation and legislation
regarding biotechnology. The goal has been to illustrate some of the
ethical issues in assessing the ethical aspects of legislation and regulation.
III. WHAT ARE POLmCAL AND ECONOMIC ISSUES?
Any effective technological innovation applied over a wide range of
population must, in a democratic society, be subjected to some societal
regulatory mechanism. In the ordinary course of events, this will mean
legislation and regulation. In the end this will involve some limitation on
the use of the technology in order to protect the common good of all
society. Deciding what should be legislated, and how, will mean that
public policy must be derived from a careful balancing of scientific
knowledge, ethical principle and constitutional rights.
In this respect, stem cell research is a paradigm case. The difficulties of
striking a reasonable balance were illustrated on August 6, 2001 when
President George W. Bush announced his decision on the use of federal
funds for stem cell research. The President attempted, with great
sensitivity, to balance the putative therapeutic benefits of stem cell
research with the respect owed the life of the human embryo. He also
tried to consider the divided opinions of Americans on these issues. As a
result, he struck a politically attractive compromise of the ethical and
scientific issues.
On the one hand, the President affirmed the sanctity of the life of the
embryo by forbidding further destruction of frozen embryos. On the
15. Rick Weiss, Stem Cell Research and the Future of Regenerative Medicine,
Broader Stem Cell Research Backed, WASH. POST, Sept. 11, 2001, at 1.
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other, he permitted use of existing cell lines, which had been harvested
after the destruction of human embryos. He established a Commission to
examine ethical issues as they arise, authorized funding for research in
adult stem cells not involving embryo destruction and forbade human
cloning for any reason. The President's rulings applied only to the use of
federal and not private funding.
As the debate resumes, the focus will be on the ethical principles
mentioned earlier in this essay and, in the public arena. It will also involve
the principles of freedom of choice and social justice. State and federal
legislators must confront the practical problem of protecting the rights of
freedom, personal choice, privacy and conscience. They must also
consider the life of the embryo, while avoiding exploitation in the use of
the knowledge and power of this new technology.
There is no way such power can be left entirely to the individual choice
of investigators, entrepreneurs or private persons. To argue that the
pursuit of knowledge, even if ostensibly for human good, should be
unrestricted is to submit the public good to the fortuitous will of a small
group of experts and entrepreneurs. Some undoubtedly will be ethically
responsive, while others will not. History and the frequency curve of the
distribution of the moral sense among people do not justify such na'fve
confidence.
In any case, personal freedom and autonomy are neither ethical nor
legal absolutes. To live in society peaceably and safely, certain restrictions
on both have always been necessary in civilized societies. However, once
public policy has been decided, the choice between using a new technology
or not using the results of stem cell research will reside with the individual.
Those who find a policy morally reprehensible should be free, within the
methods available in a democratic society, to object and to work for
changes in the policy.
A clear distinction must be preserved between what is legislated and
legal and what is moral. Legality does not confer moral status upon stem
cell research anymore than it confers moral status upon abortion or
euthanasia. Given the moral and religious diversity of present day
America and the greater diversity of its future, we must expect to live with
such differences peaceably. We must depend on persuasion, debate and
clarification of differences when public policy violates our sense of what is
morally permissible.
This surely seems to be the future for such technological innovations as
stem cell research, genetic engineering and therapy and perhaps even
cloning. On the other hand, if a particular technology is deemed ethically
wrong, then it should be forbidden in the private as well as the publicly
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supported sector. Surely, the morality of stem cell research cannot depend
on the source of its funding. In any case, each of us will be challenged to
determine whether we can in good conscience make use of knowledge and
techniques obtained from morally improper sources of stem cells.
Whatever decision is taken as public policy, it must be arrived at and
administered justly. This means conforming to the requirements of both
commutative and distributive justice. Even when the decision regarding
what to legislate is taken, the decision must also be made to legislate
justly. This means conforming to the principle of justice - rendering to
each his due, equally to equals and unequally to unequals. This principle
operates at the level of individual relationships where it is called
commutative justice and at the societal level as distributive justice. Only a
few examples of each will be mentioned.
In the realm of commutative justice lie the moral obligations of
individual investigators to individual patients and experimental subjects
and of physicians to individual patients. Investigators are, in justice,
obliged to obtain properly informed consent; to be objective in reporting
their results; to share results that are crucial to the health of the
population with the public and other investigations. Premature and
inflated reports of success in order to gain a competitive advantage are not
morally admissible. These obligations are derived from the trust society
and persons must place in the expertise of physicians and scientific
investigators. Ensuring these and other aspects of commutative justice is a
fit subject for regulatory consideration in stem cell research legislation and
policy.
In the realm of distributive justice lie the broader political and
economic questions of availability, access, distribution, quality, cost and
ownership of any cell lines that may eventually prove useful. The
commercial possibilities already promoted by biotechnology companies
will attract interest among investors, who will be entitled to some return
on their investment. The costs of research and development will have to
be returned through the price of cell transfer treatment. If stem cells
should prove to be effective, the high cost of treatment will become a
moral issue. Disproportionate access based only on ability to pay cannot
be just in the case of a life-saving or curative treatment. Government
subsidies for the economically less advantaged will be necessary. In the
current commercialized climate of American health care, assurance of
justice in distribution will surely become a matter for legislative action.
This question of distributive justice is especially acute in stem cell
research since the cells available for federal funding come from
predominantly European and a small number of South Asian sources.
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This is a small representation of the ethnic diversity of our world. The
research currently permitted may not be transferable and consequently
may be unavailable to many ethnic groups in the U.S. and the world. Yet
on the basis of equity and justice as well as humanitarian grounds, it would
be unjust not to make these benefits available to all.
The problem of ability to pay is linked to the limited sources from
which existing cell lines have been drawn. They derive from "excess"
embryos resulting from in vitro fertilization, a costly process denied to the
poorer members of our society. If it turns out that stem cells can be
engineered to reflect the unique qualities of the humans who donate them,
then the economically less fortunate will again be left out. The same
problem arises when embryos are cloned to meet the specification of the
donors for cells of a particular type. Custom-tailored stem cells will likely
be costly and well beyond the means of the poor.
These questions will become particularly acute should there be a shift in
our health care system to one of universal entitlement. Legislators will be
heavily involved in establishing principles of fair distribution and access.
Justice and fairness are not intrinsically matters of expediency and some
concept of social justice must be evolved for access and payment when
truly effective biotechnologies appear.
The question of monopoly already looms as a genuine issue. One
corporation, for example, controls the rights over many of the stem cell
lines now eligible under President Bush's plan for federal funds.' 6 The
same corporation, Geron of Menlo Park, California, owns commercial
rights to the technology that produced Dolly, the first cloned sheep, as
well as rights to telomerase. Telomerase is an enzyme that can restore the
telomere to full length in vitro and seems to extend the age of cells.
Inhibiting telomerase might be useful in inhibiting growth in cancer cells.
Geron at present is making little or no profit on these possibilities, but its
CEO Thomas Okarma says his company aims "...to dominate the
market."' 7
Further, the patent on embryonic stem cells is held by the University of
Wisconsin Research Foundation, and Geron Corporation holds
commercial rights to six cell types and seeks to exercise its options over
twelve more. Okarma expresses a view not rare among investigators in
this field, "I am not apologetic for our intellectual property. We paid for
16. Andre Pollack, The Promise of Selling Stem Cells, N.Y. TIMES, Aug. 26,
2001, at 1.
17. Id. at 11.
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it, we earned it and we deserve it."'8 To what extent does this frank
assertion of property rights over biological material conflict with what is
owed in justice to individuals and society? Who really "owns" the cell
lines from a "donated" embryo?
Geron also has plans for "therapeutic cloning," creating new embryos
from a patient's own cells to obtain stem cells specific to the donor, thus
avoiding the dangers of immuno rejection. Another company, Advanced
Technology of San Francisco, has been formed to compete with Okarma.
Clearly, the question of how much can be left to the market and how much
is to be controlled in the public interest already presents itself. In a nation
already commodifying health care, the likelihood of extension of
commodification to human cells is unfortunately high. The fact that
Geron Corporation also has its own "ethics committee" is not at all
reassuring. Money, profit and ethics are not natural allies.
All of this is now in the private sector, which is not covered by President
Bush's recent decision. Ethical and legal constraints are at the moment
not available to protect either the embryo or the public interest. Indeed,
those who work within President Bush's constraints, like NIH and
University investigators with federal grants, look to private industry and
research to supply the cell lines they believe they need to continue their
research. 9 One need only mention these facts to appreciate how complex
and intermingled are the ethical, scientific and socio-political issues we as
a nation must face.
In a recent update, the National Institute of Health expressed
confidence that patenting of new discoveries would not affect research.
However, it mentioned neither the ethical status of such patenting nor of
its impact on the public interest. Are stem cell research and the products
it generates simply commodities? Or are there humanitarian and human
rights dimensions that are being ignored in pursuit of the principles of
utility and market economics?
Important as these considerations may be, they leave aside the question
of whether there can be two standards of morality: one for the private
sector and one for the federally funded sector. If it is morally wrong to
create new embryos to obtain stem cells on federal grants, how can it be
morally permissible to do so with private funds? This is a rather extreme
example of the difficulties created when morality is left entirely to social
convention or convenience.
18. Id.
19. Ceci Connolly and Justin Gillis, Thompson: Stem Cell Work Viable, WASH.
POST, Sept. 6, 2001, at 1.
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Very serious questions will arise in the realm of professional ethics.
Currently, this field, which deals with the obligations of physicians and
other health professions, is already in flux with many calling for a "new"
ethic. What will the professional obligations be of physicians who see a
grave moral problem in providing treatments obtained from embryonic
stem cell research dependent on destruction of the embryo?
This question will become intensely debated if stem cell treatment
becomes genuinely effective. The pressure on physicians to make stem
cell treatment available will be enormous. Must physicians be "value
neutral" as some contend and submerge their personal ethical beliefs and
provide treatment simply because they are physicians? Is it even possible
to be "value neutral" in this arena? Will compliance with a socially
accepted treatment be a condition of licensure regardless of the
physician's personal beliefs? What will be the impact on this question of
universal health care entitlement if this becomes a policy? Will physicians
morally opposed to the destruction of embryos be barred from practice or
even entry into medical school?
The same questions will apply to religiously sponsored hospitals and
other health care institutions. Will Catholic hospitals, for example, be
allowed to receive public funds or reimbursements if they do not provide a
full range of services? Will a choice have to be made between religious
sponsorship, institutional integrity and survival? Will dissenting hospitals
and physicians be limited to caring for those who share their beliefs only?
These issues touch on the much deeper question any policy must face in
a morally pluralist society. How are we to live peaceably and protect the
human rights of all citizens when we are "moral strangers", i.e. members
of communities whose ethical and or religious beliefs do not permit certain
compromises? Stem cell research is a paradigm case of the kind of
questions that will also rise with the actualization of some of the promise
of the genome project, human cloning and biological innovations as yet
unimaginable.
These are some of the inter-related and intermingled questions which
confront our society and which will generate demands for public policies,
regulations, legislation and accountability. They are inter-related in the
nexus of science, ethics and politics. Clearly, in the real world, these issues
are not so easily dissectible. Yet if they are to be examined, the nature of
each must be recognized and a proper balance struck between them.
In striking a balance, the ethical considerations should guide both the
use of science and the economic and political uses of that science. This
means that decisions may move more slowly than interested parties,
patients, biotech companies and scientists desire. If anything is clear in the
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example of stem cell research, it is that haste, overselling of results and
political pressure can lead to more conflict rather than less. The debate
has only begun. All of the general public will be either victims or
beneficiaries of our collective deliberations. Let us hope that they are
morally sound, scientifically correct and politically just.

